MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
Provided By PR Newswire
Last update: Nov 4, 2025
New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration
DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidutide in Pre-clinical Models
Read more at prnewswire.com0.7502
+0.04 (+5.16%)
Find more stocks in the Stock Screener
MTVA Latest News and Analysis
